Long-term outcome after venom immunotherapy

Area of Science:

• Allergy and Immunology
• Clinical Medicine
• Toxicology

Background:

• Venom immunotherapy (VIT) is a crucial treatment for insect sting allergies.
• Limited research exists on long-term outcomes after discontinuing VIT.
• Existing studies suggest continued protection for most patients post-treatment.

Purpose of the Study:

• To review current evidence on discontinuing VIT.
• To emphasize long-term outcomes after stopping treatment.
• To inform guidelines and practice parameters for VIT cessation.

Main Methods:

• Systematic review of published literature on VIT discontinuation.
• Analysis of studies examining short-term and long-term outcomes.
• Inclusion of recent findings and high-risk factor identification.

Main Results:

• Most patients remain protected after stopping VIT, with a low risk of severe reactions (<3%).
• Systemic reactions to stings occur in approximately 15% of patients after VIT cessation.
• Mastocytosis or elevated baseline serum tryptase significantly increases relapse and mortality risk post-discontinuation.

Conclusions:

• Current guidelines for discontinuing VIT are supported by existing evidence.
• Long-term follow-up is essential, especially for high-risk patient groups.
• Further research is needed on optimal VIT duration and long-term efficacy.